迪瑞医疗：纾压蓄力，国际市场继续夯实发展根基

Core Viewpoint - The company is facing short-term challenges in its domestic market due to intensified competition and asset impairment, but it is actively working to stabilize and improve its domestic business while also achieving significant growth in its international operations [1][3][4]. Domestic Market Performance - The company anticipates a significant improvement in cash flow for 2025, projecting a return to positive cash flow compared to the previous year, with net cash flow from operating activities reported at -295 million yuan and -84,300 yuan for 2024 and the first half of 2025, respectively [1][3]. - Efforts to improve cash flow include better collection of accounts receivable, comprehensive cost control, and asset disposals, which will help reduce bad debt risk and enhance liquidity [1][3]. International Market Growth - The company reported overseas revenue of 224 million yuan for the first half of 2025, representing a year-on-year increase of 24.02%, with growth observed in markets such as India, the Philippines, and Turkey [4]. - The company has been actively expanding its international market presence for over 20 years, exporting to more than 120 countries and regions, and has entered a new phase of development characterized by localized management and operations [2][4]. - Recent achievements include winning multiple instrument contracts in India and successfully installing laboratory solutions in Romania, indicating a strong foothold in international markets [5]. Strategic Initiatives - For 2026, the company plans to strengthen its international market position with a "2+2+10" strategy, focusing on deepening its presence in 10 selected countries to enhance its competitive capabilities [6].